

INTERNATIONAL DIVISION

Tel.: +33 (0)4 72 80 23 85 • Fax: +33 (0)4 72 80 73 56
E-mail: international@biomnis.eurofinseu.com

Customer number:

Date :
EDTA whole blood sample

Laboratory's stamp
or bar code sticker

CONSENT PRIOR TO THE CARRYING OUT OF GENETIC EXAMINATIONS OF AN INDIVIDUAL

(In accordance with Articles R.1131-4,
R.1131-4-1, R.1131-4-2 and R.1131-5
of the French Public Health Code).

I, the undersigned
born on
► hereby declare that I had consultation with Dr:

where information on the genetic tests to be
performed for the reasons listed below was
provided:

- ☐ to confirm or invalidate the diagnosis of a
genetic disease in relation to my symptoms,
those of my minor child or those of the adult
person under guardianship for whom I am the
legal representative;
- ☐ confirm or deny the pre-symptomatic diagnosis
of a genetic disease;
- ☐ to identify a healthy carrier status (heterozy-
gous or chromosomal rearrangement);
- ☐ assess genetic susceptibility to disease or
drug treatment.

► To this end, I consent

- ☐ to the sample to be taken from my home
- ☐ to the deduction that will be made from my
minor child or a person of full age under guar-
dianship for whom I am the legal representative

I am informed that the results of the examination of
the genetic characteristics will be transmitted to me
by the above-mentioned Doctor in the framework of
an individual consultation. If the examination reveals
results other than those sought, the aforementioned
Doctor will determine the appropriate course of
action during an individual consultation.

► If part of the sample remains unused after examination:

- ☐ I agree that it may be integrated, if necessary,
for scientific research purposes. In this case,
all medical data concerning me will be protected
by complete anonymisation. Consequently,
I am aware that these scientific studies carried
out will not be of any benefit or prejudice to me.

Signed in (city)
on

Patient's signature, signature of the holders of
the parental authority of the child or the guardian
of the adult under guardianship:

DECLARATION OF MEDICAL CONSULTATION

(French Decree n° 2008-321 dated 4 April
2008 - French Decree dated 27 May 2013).

I, the undersigned
R.1131-4, R.1131-4-1, R.1131-4-2 and R.1131-5 of
the French Public Health Code, hereby certify that
the patient mentioned above was received for a
consultation today where information on the char-
acteristics of the disease to be screened, the methods
used to detect it and details on the possibilities of
prevention and treatment were provided.

Signed in (city)
on

Physician's signature:

PRESCRIBING CLINICIAN

First name(s): Surname :
Address:
Post code: City : Country:
Tel.: Fax:

PATIENT

First name(s): Surname :
Birth name:
Date of birth* : Gender: ☐ F ☐ M
Address:
Post code: City:
Country: Tel.:

* If the patient is a minor, consent must be given by the holders of parental authority.

CLINICAL SIGNS - This section must be completed

Date of sampling:

SAMPLE TYPE - This section must be completed

☐ EDTA whole blood ☐ Other - please specify :

MOLECULAR GENETICS TEST REQUEST FORM

- ☐ Alpha 1-antitrypsin (S and Z variants) (A1BM)
- ☐ Hereditary transthyretin amyloidosis : Molecular study of the TTR gene (TTR)
- ☐ Angelman syndrome (Postnatal: SNRPS / Prenatal : SNRPL)
- ☐ Uniparental disomy (DUPRE)
- ☐ Exome (EXOME): specific request form required, please see www.eurofins-biomnis.com
- ☐ Factor II (mutation g.20210G>A) (F2M)
- ☐ Factor V Leiden (mutation p.Arg506Glu) (F5L)
- ☐ Familial Mediterranean Fever (FMF) - study of the MEFV gene (FMF): please attach
the completed clinical information form which is available on www.eurofins-biomnis.com
- ☐ CYP2C19 *2/*3 alleles genotyping (CYP2C)
- ☐ ApoE genotyping (APEBM), in the context of: ☐ dyslipidemia ☐ neurodegenerative disease
- ☐ DPD genotyping (5FUGE)
- ☐ IL-28B genotyping (IL28B)
- ☐ RHD genotyping (BMGR)
- ☐ Gilbert syndrome (polymorphism UGT1A1*28) (GILB)
- ☐ Haemochromatosis: mutation p.Cys282Tyr (HMC)
- ☐ Haemochromatosis: mutation p.His63Asp (H63D)
- ☐ Haemochromatosis: mutation p.Ser65Cys (S65C)
- ☐ HLA class I - HLA-C genotyping (HLCT)
- ☐ HLA class I (loci A, B) (HLA1) : ☐ A*29 ☐ B*27 ☐ B*51 ☐ B*57
- ☐ HLA classe II (loci DQ, DR) (HLA2) : ☐ DR4 ☐ DQ2 ☐ DQ8 ☐ DQB1*0602
- ☐ HLA-B*27 (B27BM)
- ☐ Lactose intolerance (LCT)
- ☐ Y chromosome microdeletions (loci AZFa, AZFb and AZFc) (DELY)
- ☐ MTHFR (Methylene Tetrahydrofolate Reductase - thermolabile variant, mutation c.677C>T) (MTHFR)
- ☐ MTHFR (Methylene Tetrahydrofolate Reductase, mutation c.1298A>C) (MTHF2)
- ☐ MUC1 Variation 27dupC (MUC1)
- ☐ Cystic fibrosis (CFTR, next-generation sequencing) (MUCO)
- ☐ Prader-Willi syndrome (Postnatal: SNRPS / Prenatal: SNRPL)
- ☐ DNA microarray (SNP array) (SNPRE)
- ☐ qPCR: contact us (QPOST) (attach the R66-INTGB information form)
- ☐ Sanger: contact us (SEPOS) (attach the R66-INTGB information form)
- ☐ Fragile X syndrome (Postnatal: XFRA / Prenatal: XFRAP)
- ☐ UGT1A1 - Evaluation of the toxic risk of irinotecan (UGT1A)
- ☐ Other - please specify: